Insights into the operational model of agonism of receptor dimers

References

• Kenakin T. Efficacy in drug receptor theory: outdated concept or under-valued tool? Trends Pharmacol Sci. 1999;20(10):400–405.
   PubMed Web of Science ®Google Scholar
• Black JW, Leff P. Operational models of pharmacological agonism. Proc R Soc London Ser B, Biol Sci. 1983;220:141–162.
   PubMed Web of Science ®Google Scholar
• Black JW, Leff P, Shankley NP, et al. An operational model of pharmacological agonism: the effect of E/[A] curve shape on agonist dissociation constant estimation. Br J Pharmacol. 1985;84(2):561–571.
   PubMed Web of Science ®Google Scholar
• Kenakin T, Watson C, Muniz-Medina V, et al. A simple method for quantifying functional selectivity and agonist bias. ACS Chem Neurosci. 2012;3(3): 193–203.
   PubMed Web of Science ®Google Scholar
• Kenakin T. Functional selectivity and biased receptor signaling. J Pharmacol Exp Ther. 2011;336(2):296–302.
   PubMed Web of Science ®Google Scholar
• Kenakin T. A scale of agonism and allosteric modulation for assessment of selectivity, bias, and receptor mutation. Mol Pharmacol. 2017;92(4):414–424.
   PubMed Web of Science ®Google Scholar
• Kolb P, Kenakin T, Alexander SPH, et al. Community guidelines for GPCR ligand bias: IUPHAR review 32. Br J Pharmacol. 2022;179(14):3651–3674.
   PubMed Web of Science ®Google Scholar
• Cecchini M, Changeux J-P. Nicotinic receptors: from protein allostery to computational neuropharmacology. Mol Aspects Med. 2022;84:101044.
   PubMed Web of Science ®Google Scholar
• Salussolia CL, Prodromou ML, Borker P, et al. Arrangement of subunits in functional NMDA receptors. J Neurosci. 2011;31(31):11295–11304.
   PubMed Web of Science ®Google Scholar
• Romano C, Yang WL, O’Malley KL. Metabotropic glutamate receptor 5 is a disulfide-linked dimer. J Biol Chem. 1996;271(45):28612–28616.
   PubMed Web of Science ®Google Scholar
• Cvejic S, a DL. Dimerization of the delta opioid receptor: implication for a role in receptor internalization. J Biol Chem. 1997;272(43):26959–26964.
   PubMed Web of Science ®Google Scholar
• Fujita W, Gomes I, Devi LA. Heteromers of μ-δ opioid receptors: new pharmacology and novel therapeutic possibilities. Br J Pharmacol. 2015;172(2):375–387.
   PubMed Web of Science ®Google Scholar
• Hojo M, Sudo Y, Ando Y, et al. mu-Opioid receptor forms a functional heterodimer with cannabinoid CB1 receptor: electrophysiological and FRET assay analysis. J Pharmacol Sci. 2008;108(3):308–319.
   PubMed Web of Science ®Google Scholar
• Bushlin I, Gupta A, Stockton SD, et al. Dimerization with cannabinoid receptors allosterically modulates delta opioid receptor activity during neuropathic pain. PLoS One. 2012;7(12):e49789.
   PubMed Web of Science ®Google Scholar
• Redka DS, Morizumi T, Elmslie G, et al. Coupling of G proteins to reconstituted monomers and tetramers of the M2 muscarinic receptor. J Biol Chem. 2014;289(35):24347–24365.
   PubMed Web of Science ®Google Scholar
• Liste MJV, Caltabiano G, Ward RJ, et al. The Molecular Basis of Oligomeric Organization of the Human M 3 Muscarinic Acetylcholine Receptor. Mol Pharmacol. 2015;87(6):936–953.
   PubMed Web of Science ®Google Scholar
• Springael J-Y, Urizar E, Costagliola S, et al. Allosteric properties of G protein-coupled receptor oligomers. Pharmacol Ther. 2007;115(3):410–418.
   PubMed Web of Science ®Google Scholar
• Han Y, Moreira IS, Urizar E, et al. Allosteric communication between protomers of dopamine class A GPCR dimers modulates activation. Nat Chem Biol. 2009;5(9):688–695.
   PubMed Web of Science ®Google Scholar
• Smith NJ, Milligan G, Sibley D. Allostery at G protein-coupled receptor homo- and heteromers: uncharted pharmacological landscapes. Pharmacol Rev. 2010;62(4):701–725.
   PubMed Web of Science ®Google Scholar
• Chabre M, Deterre P, Antonny B. The apparent cooperativity of some GPCRs does not necessarily imply dimerization. Trends Pharmacol Sci. 2009;30(4):182–187.
   PubMed Web of Science ®Google Scholar
• Milligan G. The prevalence, maintenance, and relevance of G protein-coupled receptor oligomerization. Mol Pharmacol. 2013;84(1):158–169.
   PubMed Web of Science ®Google Scholar
• Sleno R, Hébert TE. The dynamics of GPCR oligomerization and their functional consequences. Int Rev Cell Mol Biol. 2018;338:141–171.
   PubMed Web of Science ®Google Scholar
• Milligan G, Ward RJ, Marsango S. GPCR homo-oligomerization. Curr Opin Cell Biol. 2019;57:40–47.
   PubMed Web of Science ®Google Scholar
• Dijkman PM, Castell OK, Goddard AD, et al. Dynamic tuneable G protein-coupled receptor monomer-dimer populations. Nat Commun. 2018; 9(1). 10.1038/s41467-018-03727-6
   Google Scholar
• Zhou B, Giraldo J. An operational model for GPCR homodimers and its application in the analysis of biased signaling. Drug Discov Today. 2018;23(9):1591–1595.
   PubMed Web of Science ®Google Scholar
• Kukkonen JP. Allosteric interactions via the orthosteric ligand binding sites in a constitutive G-protein-coupled receptor homodimer. Pharmacol Res. 2021;166:105116.
   PubMed Web of Science ®Google Scholar
• Cechova K, Lan C, Macik M, et al. Kappa but not delta or mu opioid receptors form homodimers at low membrane densities. Cell Mol Life Sci. 2021;78(23):7557–7568.
   PubMed Web of Science ®Google Scholar
• Angers S, Salahpour A, Joly E, et al. Detection of beta 2-adrenergic receptor dimerization in living cells using bioluminescence resonance energy transfer (BRET). Proc Natl Acad Sci U S A. 2000;97(7):3684–3689.
   PubMed Web of Science ®Google Scholar
• Ciruela F, Fernández-Dueñas V. GPCR oligomerization analysis by means of BRET and dFRAP. Methods Mol Biol. 2015;1272:133–141.
   PubMedGoogle Scholar
• Limbird LE, Lefkowitz RJ. Negative cooperativity among beta-adrenergic receptors in frog erythrocyte membranes. J Biol Chem. 1976;251(16):5007–5014.
   PubMed Web of Science ®Google Scholar
• Fraser CM, Venter JC. The size of the mammalian lung beta 2-adrenergic receptor as determined by target size analysis and immunoaffinity chromatography. Biochem Biophys Res Commun. 1982;109(1):21–29.
   PubMed Web of Science ®Google Scholar
• Venter JC, Schaber JS, U’Prichard DC, et al. Molecular size of the human platelet alpha 2-adrenergic receptor as determined by radiation inactivation. Biochem Biophys Res Commun. 1983;116(3):1070–1075.
   PubMed Web of Science ®Google Scholar
• Venter JC, Horne P, Eddy B, et al. Alpha 1-adrenergic receptor structure. Mol Pharmacol. 1984;26(2):196–205.
   PubMed Web of Science ®Google Scholar
• Jordan BA, Devi LA. G-protein-coupled receptor heterodimerization modulates receptor function. Nature. 1999;399(6737):697–700.
   PubMed Web of Science ®Google Scholar
• Rossi M, Maggio R, Fasciani I, et al. Historical perspectives: from monomers to dimers and beyond, an exciting journey in the world of G protein-coupled receptors BT - G-protein-coupled receptor dimers. Herrick-Davis K, Milligan G, Di Giovanni G, editors. Cham: Springer International Publishing; 2017. p. 3–14.
   Google Scholar
• Tiwari VV, He S-Q, Huang Q, et al. Activation of µ-δ opioid receptor heteromers inhibits neuropathic pain behavior in rodents. Pain. 2020;161(4):842–855.
   PubMed Web of Science ®Google Scholar
• Hiller C, Kühhorn J, Gmeiner P. Class A G-protein-coupled receptor (GPCR) dimers and bivalent ligands. J Med Chem. 2013;56(17):6542–6559.
   PubMed Web of Science ®Google Scholar
• Newman AH, Battiti FO, Bonifazi A. 2016 Philip S. portoghese medicinal chemistry lectureship: designing bivalent or bitopic molecules for G-protein coupled receptors. The whole is greater than the sum of its parts. J Med Chem. 2020;63(5):1779–1797.
   PubMed Web of Science ®Google Scholar
• Romantini N, Alam S, Dobitz S, et al. Exploring the signaling space of a GPCR using bivalent ligands with a rigid oligoproline backbone. Proc Natl Acad Sci U S A. 2021;118(48):e2108776118.
   PubMed Web of Science ®Google Scholar
• Pellissier LP, Barthet G, Gaven F, et al. G protein activation by serotonin type 4 receptor dimers: evidence that turning on two protomers is more efficient. J Biol Chem. 2011;286(12):9985–9997.
   PubMed Web of Science ®Google Scholar
• Harikumar KG, Wootten D, Pinon DI, et al. Glucagon-like peptide-1 receptor dimerization differentially regulates agonist signaling but does not affect small molecule allostery. Proc Natl Acad Sci U S A. 2012;109(45):18607–18612.
   PubMed Web of Science ®Google Scholar
• Hlavackova V, Goudet C, Kniazeff J, et al. Evidence for a single heptahelical domain being turned on upon activation of a dimeric GPCR. EMBO J. 2005;24(3):499–509.
   PubMed Web of Science ®Google Scholar
• Minic J, Persuy M-A, Godel E, et al. Functional expression of olfactory receptors in yeast and development of a bioassay for odorant screening. FEBS J. 2005;272(2):524–537.
   PubMed Web of Science ®Google Scholar
• Wade F, Espagne A, Persuy M-A, et al. Relationship between homo-oligomerization of a mammalian olfactory receptor and its activation state demonstrated by bioluminescence resonance energy transfer. J Biol Chem. 2011;286(17):15252–15259.
   PubMed Web of Science ®Google Scholar
• Harpsøe K, Ahring PK, Christensen JK, et al. Unraveling the high- and low-sensitivity agonist responses of nicotinic acetylcholine receptors. J Neurosci. 2011;31(30):10759–10766.
   PubMed Web of Science ®Google Scholar
• Ahring PK, Olsen JA, Nielsen EØ, et al. Engineered α4β2 nicotinic acetylcholine receptors as models for measuring agonist binding and effect at the orthosteric low-affinity α4-α4 interface. Neuropharmacology. 2015;92:135–145.
   PubMed Web of Science ®Google Scholar
• Wongsamitkul N, Maldifassi MC, Simeone X, et al. α subunits in GABAA receptors are dispensable for GABA and diazepam action. Sci Rep. 2017;7(1):15498.
   PubMedGoogle Scholar
• Ziemba AM, Forman SA. Correction for inhibition leads to an allosteric co-agonist model for pentobarbital modulation and activation of α1β3γ2L GABAA receptors. PLoS One. 2016;11:e0154031.
   PubMed Web of Science ®Google Scholar
• Roche D, van der Graaf PH, Giraldo J. Have many estimates of efficacy and affinity been misled? Revisiting the operational model of agonism. Drug Discov Today. 2016;21(11):1735–1739.
   PubMed Web of Science ®Google Scholar
• Gregory KJ, Giraldo J, Diao J, et al. Evaluation of operational models of agonism and allosterism at receptors with multiple orthosteric binding sites. Mol Pharmacol. 2020;97(1): 35–45.
   PubMed Web of Science ®Google Scholar
• Furchgott RF. The use of β-haloalkylamines in the differentiation of receptors and in the determination of dissociation constants of receptor-agonist complexes. Adv Drug Res. 1966;3:21–55.
   Google Scholar
• Jakubík J, Randáková A, Rudajev V, et al. Applications and limitations of fitting of the operational model to determine relative efficacies of agonists. Sci Rep. 2019;9(1): 4637.
   PubMedGoogle Scholar
• Jakubík J, Randáková A, Chetverikov N, et al. The operational model of allosteric modulation of pharmacological agonism. Sci Rep. 2020;10(1):14421.
   PubMed Web of Science ®Google Scholar
• Zhu X, Finlay DB, Glass M, et al. An evaluation of the operational model when applied to quantify functional selectivity. Br J Pharmacol. 2018;175(10):1654–1668.
   PubMed Web of Science ®Google Scholar
• Buchwald P. A receptor model with binding affinity, activation efficacy, and signal amplification parameters for complex fractional response versus occupancy data. Front Pharmacol. 2019;10:605.
   PubMed Web of Science ®Google Scholar
• Onaran HO, Ambrosio C, Uğur Ö, et al. Systematic errors in detecting biased agonism: analysis of current methods and development of a new model-free approach. Sci Rep. 2017;7(1): 44247.
   PubMedGoogle Scholar
• Strange PG. Agonist binding, agonist affinity and agonist efficacy at G protein-coupled receptors. Br J Pharmacol. 2008;153(7):1353–1363.
   PubMed Web of Science ®Google Scholar
• Van der Graaf PH, Stam WB. Analysis of receptor inactivation experiments with the operational model of agonism yields correlated estimates of agonist affinity and efficacy. J Pharmacol Toxicol Methods. 1999;41(2–3):117–125.
   PubMed Web of Science ®Google Scholar
• Buchwald P. A single unified model for fitting simple to complex receptor response data. Sci Rep. 2020;10(1):13386.
   PubMed Web of Science ®Google Scholar
• Colquhoun D. Binding, gating, affinity and efficacy: the interpretation of structure-activity relationships for agonists and of the effects of mutating receptors. Br J Pharmacol. 1998;125(5):924–947.
   PubMed Web of Science ®Google Scholar
• Strange PG. Use of the GTPγS ([35S]GTPγS and Eu-GTPγS) binding assay for analysis of ligand potency and efficacy at G protein-coupled receptors. Br J Pharmacol. 2010;161(6):1238–1249.
   PubMed Web of Science ®Google Scholar
• Jakubík J, Janíčková H, El-Fakahany EE, et al. Negative cooperativity in binding of muscarinic receptor agonists and GDP as a measure of agonist efficacy. Br J Pharmacol. 2011;162(5):1029–1044.
   PubMed Web of Science ®Google Scholar
• DeVree BT, Mahoney JP, Vélez-Ruiz GA, et al. Allosteric coupling from G protein to the agonist-binding pocket in GPCRs. Nature. 2016;535(7610):182–186.
   PubMed Web of Science ®Google Scholar